The Triad Story
Triad Life Sciences, Inc. is an emerging regenerative medicine company with a groundbreaking FDA-cleared technology platform engineered to address unmet clinical needs in complex surgical wounds, chronic stalled wounds, and burns. Triad’s proprietary, patent-pending technology provides innovative treatment solutions derived from our naturally occurring extracellular matrix (ECM) material and its related bioactive properties.
Triad was founded to disrupt the extracellular matrix (ECM) market with a platform technology that introduces the first-ever placental-derived medical device to address the inherent challenges and related restrictions of human cells, tissues, and cellular and tissue-based products (HCT/Ps).
Triad’s leadership team has well over 100 years of collective medical device experience at multiple biologics companies and over 30 years of combined experience specific to placental ECM technologies.
This combined experience allowed Triad to identify the following three key challenges with placental allografts manufactured from HCT/Ps: graft variability, minimal manipulation requirements, and the economics of care. InnovaMatrix® Platform offers a unique, unparalleled solution to these challenges while also providing the reliability, reproducibility, and safety profile of a medical device.